<DOC>
	<DOCNO>NCT00148317</DOCNO>
	<brief_summary>PRIMARY STUDY OBJECTIVES - To evaluate efficacy combination bortezomib , dexamethasone , without DOXIL , follow high-dose cyclophosphamide therapy two different subset multiple myeloma patient : 1 . Patients post first line therapy 2 . Patients relapsed/refractory disease bortezomib-naïve - To evaluate safety combination bortezomib dexamethasone , without DOXIL , follow high-dose cyclophosphamide therapy patient multiple myeloma . SECONDARY STUDY OBJECTIVES - To evaluate role combination bortezomib dexamethasone , without DOXIL , follow high-dose cyclophosphamide ability collect &gt; 10 x 106 CD34+ cells/kg &lt; 7 collection ( subset multiple myeloma patient ) . - To evaluate survival patient receive combination bortezomib dexamethasone , without DOXIL , follow high-dose cyclophosphamide ( subsets patient ) .</brief_summary>
	<brief_title>Phase II Study Velcade , Decadron , Doxil Followed Cyclophosphamide Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Subject must voluntarily sign understand write informed consent . Confirmed diagnosis multiple myeloma specify SWOG criterion detail Appendix I. Measurable disease define follow : 1 . For patient post induction therapy , measurable paraprotein serum urine and/or plasmacytoma present physical exam imaging . 2 . For patient relapsed/refractory disease , &gt; 0.5 g/dL serum monoclonal protein , &gt; 0.1 g/dL serum free light chain , &gt; 0.2 g/24 hr urinary Mprotein excretion , and/or measurable plasmacytoma ( ) . Age &gt; = 18 year time signing informed consent form . Karnofsky performance status &gt; =70 % ( &gt; 60 % due bony involvement myeloma ) . Group A ( postinduction therapy ) patient receive one prior treatment regimen ( eg VAD , Thal/Dex , BLTD , MP , BiRD , DVd ) least 20 patient receive Revlimid base regimen Group B ( &gt; 1st line therapy ) patient relapsed/refractory multiple myeloma receive two prior treatment regimen . If patient woman childbearing age , must negative serum urine pregnancy test within 7 day start study must use effective contraception throughout course study . Life expectancy &gt; 12 week . Absolute neutrophil count ( ANC ) &gt; = 1500 cells/mm3 ( &gt; = 1000 patient bone marrow biopsy display &gt; 50 % involvement myeloma ) Platelets count &gt; = 50,000/mm3 ( &gt; = 30,000 patient bone marrow biopsy display &gt; 50 % involvement myeloma ) Hemoglobin &gt; 9.0 g/dL Serum SGOT/AST &lt; 3.0 x upper limit normal ( ULN ) Serum SGPT/ALT &lt; 3.0 x upper limit normal ( ULN ) Serum creatinine &lt; 2.5 mg/dL creatinine clearance &gt; 40ml/min Serum total bilirubin &lt; 1.5 x ULN Patients must MUGA scan LVEF &gt; 50 % Patients nonsecretory MM ( measurable monoclonal protein , free light chain , and/or Mspike blood urine ) unless measurable disease available image technique MRI PET scan . Prior treatment bortezomib . Peripheral neuropathy &gt; Grade 2 define CTCAE Version 3.0 ( see Appendix II ) History allergic reaction compound contain mannitol , bortezomib , conventional formulation doxorubicin HCL component DOXIL . Prior history malignancy ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast ) unless disease free ³ 5 year . NYHA Class III IV heart disease . History active unstable angina , congestive heart disease , serious uncontrolled cardiac arrhythmia myocardial infarction within 6 month . Female patient pregnant breastfeeding . Women childbearing potential men must agree use adequate contraception prior study entry duration study participation . Known HIV hepatitis A , B , C positivity Active viral bacterial infection coexist medical problem would significantly increase risk treatment program . Any concurrent , uncontrolled medical condition , laboratory abnormality , psychiatric illness could place him/her unacceptable risk , include , limited , uncontrolled hypertension , uncontrolled diabetes , active uncontrolled infection , and/or acute chronic liver disease ( i.e. , hepatitis , cirrhosis ) . No prior antimyeloma therapy within 2 week treatment initiation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>